Next Article in Journal
Olesoxime (TRO19622): A Novel Mitochondrial-Targeted Neuroprotective Compound
Next Article in Special Issue
Deregulation of Interferon Signaling in Malignant Cells
Previous Article in Journal
Nitric Oxide Synthase Inhibitors as Antidepressants
Previous Article in Special Issue
Interferons as Therapy for Viral and Neoplastic Diseases: From Panacea to Pariah to Paragon
Pharmaceuticals 2010, 3(2), 323-344; doi:10.3390/ph3020323
Review

Oromucosal Administration of Interferon to Humans

1,* , 2
,
1
 and
2
1 School of Biomedical, Biomolecular and Chemical Sciences, University of Western Australia, 35 Stirling Highway, Crawley WA 6009, Australia 2 Amarillo Biosciences, Inc., 4134 Business Park Drive, Amarillo, TX 79110, USA
* Author to whom correspondence should be addressed.
Received: 1 December 2009 / Revised: 20 January 2010 / Accepted: 25 January 2010 / Published: 28 January 2010
(This article belongs to the Special Issue Interferons)
View Full-Text   |   Download PDF [337 KB, uploaded 28 January 2010]

Abstract

The prevailing dogma is that, to be systemically effective, interferon-alpha (IFNα) must be administered in sufficiently high doses to yield functional blood concentrations. Such an approach to IFNa therapy has proven effective in some instances, but high-dose parenteral IFNα therapy has the disadvantage of causing significant adverse events. Mounting evidence suggests that IFNα delivered into the oral cavity in low doses interacts with the oral mucosa in a unique manner to induce systemic host defense mechanisms without IFNα actually entering the circulation, thus reducing the potential for toxic side effects. A better understanding of the applications and potential benefits of this treatment modality are under active investigation. This paper provides a review of the relevant literature on the clinical use of the oromucosal route of administration of interferon, with an emphasis on the treatment of influenza.
Keywords: interferon; oromucosal delivery; influenza; treatment; viral diseases interferon; oromucosal delivery; influenza; treatment; viral diseases
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote
MDPI and ACS Style

Beilharz, M.W.; Cummins, M.J.; Bennett, A.L.; Cummins, J.M. Oromucosal Administration of Interferon to Humans. Pharmaceuticals 2010, 3, 323-344.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here

Comments

Cited By

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert